Table 1. Clinicopathological features of patients.
| Primary site | Pancreatic | Non-pancreatic | All |
|---|---|---|---|
| Number | 49 | 33 | 82 |
| Median age (range) | 54.9 (24.4–81.6) | 57.4 (22.2–67.7) | 55.4 (22.2–81.6) |
| Male | 27 | 15 | 42 |
| Female | 22 | 18 | 40 |
| Performance status | |||
| 0–1 | 44 | 27 | 71 |
| ⩾2 | 5 | 6 | 11 |
| Site | |||
| Lung | — | 8 | — |
| GI tract | — | 9 | — |
| Ovarian | — | 1 | — |
| Unknown | — | 15 | — |
| Differentiation | |||
| Well | 36 | 21 | 57 |
| Poorly | 9 | 9 | 18 |
| Grade | |||
| Low (1) | 4 | 4 | 8 |
| Intermediate (2) | 31 | 16 | 47 |
| High (3) | 5 | 10 | 15 |
| Unknown | 9 | 3 | 12 |
| Sites of metastases | |||
| None | 5 | 4 | 9 |
| Liver | 41 | 21 | 62 |
| Lymph node | 13 | 14 | 27 |
| Lung | 7 | 7 | 14 |
| Bone | 6 | 5 | 11 |
| Other | 10 | 6 | 16 |
| Prior systemic therapy | |||
| None | 33 | 24 | 57 |
| Radionucleotide | 4 | 3 | 7 |
| Embolisation | 3 | 0 | 3 |
| Interferon | 2 | 1 | 3 |
| Octreotide | 8 | 7 | 15 |
| Radiotherapy | 0 | 1 | 1 |
| Octreotide scintigraphy | |||
| Positive | 39 | 18 | 57 |
| Negative | 9 | 11 | 20 |
| 5HIAA urine | |||
| Positive | 4 | 7 | 11 |
| Negative | 21 | 16 | 37 |
| Chromogranin A | |||
| Positive (>60 U l−1) | 17 | 10 | 27 |
| Negative (≤ 60 U l−1) | 9 | 10 | 19 |
| Tumour type | |||
| Non-functional | 38 | 31 | 69 |
| Gastrinoma | 5 | 0 | 5 |
| Glucagonoma | 4 | 1 | 5 |
| Somatostatinoma | 1 | 1 | 2 |
| Vipoma | 1 | 0 | 1 |
Abbreviations: GI=gastrointestinal; 5HIAA=5-hydroxyindoleacetic acid.